During Ramadan fasting, documented symptomatic hypoglycemia was numerically lower with lixisenatide (3.3%, 3/91) than with sulfonylurea (8.9%, 8/90), each with basal insulin.
In plain wordsDuring Ramadan fasting, symptomatic low blood sugar was numerically lower with lixisenatide (3.3%) than with sulfonylurea (8.9%), each with basal insulin.
- Peptide
- Lixisenatide
- Outcome
- DecreaseDocumented symptomatic hypoglycemia during Ramadan
- Study
n = 181
- Comparator
- Sulfonylurea with basal insulin
- Analysis
- Primary
- Outcome group
- Adverse events · Metabolic and weight
- Studied dose
- Dose not stated
Measurements
- Participants with event
- 3.3%
- lixisenatide
- Events
- 3 participants
- lixisenatide, 91 assessed
- Participants with event
- 8.9%
- sulfonylurea
- Events
- 8 participants
- sulfonylurea, 90 assessed
- Odds ratio
- 0.34 ratio
- 95% CI 0.09, 1.35
- Proportion difference
- −0.06 proportion
- 95% CI -0.13, 0.01
Source sentences
A numerically lower percentage of participants with lixisenatide + BI (3.3%, 3/91) versus SU + BI (8.9%, 8/90) had ≥1 documented symptomatic hypoglycemia event (intent-to-treat visit 4) during Ramadan fasting (OR: 0.34; 95% CI 0.09, 1.35; proportion difference -0.06, 95% CI -0.13, 0.01)
2 context sentences(design, population, supporting numbers)
Adding lixisenatide to basal insulin (BI) instead of sulfonylurea (SU), versus continuing SU + BI was assessed in people with type 2 diabetes mellitus (T2DM) who intended to fast during Ramadan 2017.
LixiRam (NCT02941367) was a phase 4, randomized, open-label, 12-22-week study in people with T2DM insufficiently controlled with SU + BI ± 1 oral anti-diabetic.